|
US6994851B1
(en)
*
|
1997-07-10 |
2006-02-07 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
WO1999051263A2
(en)
*
|
1998-04-08 |
1999-10-14 |
University Of North Carolina At Chapel Hill |
Methods and modified cells for the treatment of cancer
|
|
US6844188B1
(en)
|
1998-04-08 |
2005-01-18 |
University Of North Carolina At Chapel Hill |
Methods and modified cells for the treatment of cancer
|
|
US7935805B1
(en)
*
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
PT1141315E
(pt)
|
1998-12-31 |
2008-05-05 |
Novartis Vaccines & Diagnostic |
Polipéptidos do envelope (env) de hiv modificados
|
|
EP1980617A1
(en)
*
|
1998-12-31 |
2008-10-15 |
Novartis Vaccines and Diagnostics, Inc. |
Improved expression of HIV polypeptides and production of virus-like particles
|
|
WO2000039304A2
(en)
*
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
US8128922B2
(en)
|
1999-10-20 |
2012-03-06 |
Johns Hopkins University |
Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
|
|
US7342002B2
(en)
*
|
2000-08-03 |
2008-03-11 |
The Johns Hopkins University |
Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
|
|
GB0026812D0
(en)
*
|
2000-11-02 |
2000-12-20 |
Isis Innovation |
Cancer therapy
|
|
NZ530635A
(en)
*
|
2001-06-15 |
2007-03-30 |
Nordic Vaccine Technology As |
Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
|
|
AU2002320314A1
(en)
*
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
JP4302513B2
(ja)
*
|
2001-07-05 |
2009-07-29 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
|
|
US20030170614A1
(en)
*
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
|
JP2005521380A
(ja)
*
|
2001-08-31 |
2005-07-21 |
カイロン コーポレイション |
抗原性ｂ型ｈｉｖポリペプチドをコードするポリヌクレオチド、そのポリペプチドおよびそれらの使用
|
|
ES2456666T3
(es)
*
|
2003-04-18 |
2014-04-23 |
Biotech Synergy, Inc. |
Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
|
|
WO2004098526A2
(en)
*
|
2003-05-05 |
2004-11-18 |
Johns Hopkins University |
Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
|
|
WO2004100984A1
(en)
*
|
2003-05-13 |
2004-11-25 |
The University Of Massachusetts |
Endogenous adjuvant molecules and uses thereof
|
|
WO2006085983A2
(en)
*
|
2004-07-09 |
2006-08-17 |
University Of North Carolina At Chapel Hill |
Viral adjuvants
|
|
CA2594040A1
(en)
*
|
2005-01-06 |
2006-07-13 |
The Johns Hopkins University |
Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
|
|
CA2595726A1
(en)
*
|
2005-01-26 |
2006-08-03 |
The Johns Hopkins University |
Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
|
|
AU2006302794B2
(en)
*
|
2005-02-15 |
2011-08-04 |
Children's Hospital, Inc. |
New live virus vaccines
|
|
WO2008024844A2
(en)
*
|
2006-08-22 |
2008-02-28 |
The Johns Hopkins University |
Anticancer combination therapies
|
|
US9085638B2
(en)
|
2007-03-07 |
2015-07-21 |
The Johns Hopkins University |
DNA vaccine enhancement with MHC class II activators
|
|
US20080260765A1
(en)
*
|
2007-03-15 |
2008-10-23 |
Johns Hopkins University |
HPV DNA Vaccines and Methods of Use Thereof
|
|
US20090285861A1
(en)
*
|
2008-04-17 |
2009-11-19 |
Tzyy-Choou Wu |
Tumor cell-based cancer immunotherapeutic compositions and methods
|
|
CA2793959C
(en)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
PT2691530T
(pt)
|
2011-06-10 |
2018-05-10 |
Univ Oregon Health & Science |
Glicoproteínas e vectores recombinantes cmv
|
|
EP2568289A3
(en)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US11559504B2
(en)
*
|
2017-06-02 |
2023-01-24 |
The Penn State Research Foundation |
Ceramide nanoliposomes, compositions and methods of using for immunotherapy
|
|
TW202120122A
(zh)
*
|
2019-08-13 |
2021-06-01 |
國立研究開發法人醫藥基盤・健康・營養研究所 |
基於免疫記憶之新穎疾病治療及預防
|